MYL up +1.51% percent right now. $MYL High is at 54.10 and

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 3:34 PM

MYL up +1.51% percent right now. $MYL High is at 54.10 and the Low 52.44 with current volume of 889,069.

Recent News posted below.

MYL Mylan Inc Recent Headline News

KaloBios (KBIO) Looks Good: Stocks Adds 11.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:25AM CST
KaloBios (KBIO) was a big mover last session, with shares rising over 11% on the day.
MNK: 93.09 (+2.03), IPXL: 29.00 (+0.43), KBIO: 1.93 (+0.13), MYL: 53.84 (+0.73)

Comparing America's 3 Largest Generic Drugs Companies
Joseph Cafariello - at Seeking Alpha - Fri Nov 07, 9:05AM CST

ZTS: 40.18 (-0.05), ACT: 245.77 (-0.14), MYL: 53.84 (+0.73)

Mylan Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to EpiPen® (epinephrine) Auto-Injectors
PR Newswire - Fri Nov 07, 7:00AM CST
Mylan Inc. (Nasdaq: MYL) today announced it has signed a multi-year strategic alliance agreement with Walt Disney Parks and Resorts to help increase awareness of anaphylaxis, a life-threatening (severe) allergic reaction. The agreement includes updated maps in Disney's domestic theme parks and on its cruise ships as well as updated signage in the parks that highlight locations with EpiPen® (epinephrine) and EpiPen Jr® (epinephrine) Auto-Injectors. Over time, the companies also will introduce a variety of educational resources designed to increase awareness of and preparedness for severe allergic reactions.
MYL: 53.84 (+0.73)

Mylan reports market availability of generic Loestrin 24 Fe for contraception
M2 - Thu Nov 06, 7:27AM CST
Pharmaceutical company Mylan (NasdaqGS:MYL) revealed on Wednesday the introduction of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate in the US with immediate effect.
MYL: 53.84 (+0.73)

Actavis Beats on Q3 Earnings, Guides Above Expectations - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 9:16AM CST
Actavis' (ACT) third quarter results were boosted by the Forest Labs and Warner Chilcott acquisitions.
MNK: 93.09 (+2.03), ACT: 245.77 (-0.14), MYL: 53.84 (+0.73), TEVA: 58.11 (+0.41)

Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.44 (+0.20), BCR: 163.25 (+0.87), INCY: 70.70 (+1.38), MYL: 53.84 (+0.73), AEGR: 21.61 (+0.03)

Mylan Launches Generic Loestrin 24 Fe®
PR Newswire - Wed Nov 05, 6:30AM CST
Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate, which is the generic version of Warner Chilcott's Loestrin 24 Fe®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.(1) Mylan has begun shipping product.
MYL: 53.84 (+0.73)

Mylan Is Near All-Time High Levels But Still A Strong Buy
Kanak Kanti De - at Seeking Alpha - Mon Nov 03, 12:10PM CST

MYL: 53.84 (+0.73)

Watch for Shares of Mylan (MYL) to Approach Resistance at $53.74
Comtex SmarTrend(R) - Fri Oct 31, 12:59PM CDT
Shares of Mylan (NASDAQ:MYL) have bullishly opened above the pivot of $51.77 today and have reached the first resistance level of $53.06. Analysts will be watching for a cross of the next upside pivot targets of $53.74 and $55.71.
MYL: 53.84 (+0.73)

Teva Beats Q3 Earnings Expectations, Updates Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 12:10PM CDT
Teva (TEVA) has seven U.S. launches and multiple international launches lined up for the fourth quarter.
IPXL: 29.00 (+0.43), ACT: 245.71 (-0.20), MYL: 53.84 (+0.73), TEVA: 58.11 (+0.41)

Mylan updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 11:38AM CDT

MYL: 53.84 (+0.73)

Mylan Rises On Q3 Earnings Beat, Affirms Abbott Deal
at Investor's Business Daily - Fri Oct 31, 10:17AM CDT
Mylan (MYL) was up 3%, near 54, in early trading in the stock market today after the drugmaker beat Q3 estimates late Thursday. Earlier, the stock was up more than 7% at a nearly eight-month high above 56. Earnings came in on the high end of the...
ABT: 44.07 (+0.70), SHPG: 201.00 (+2.42), MYL: 53.84 (+0.73), ABBV: 63.72 (+2.22)

Mylan (MYL) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Fri Oct 31, 10:16AM CDT
The following Mylan (MYL) conference call took place on October 30, 2014, 04:30 PM ET. This is a transcript of that earnings call:
MYL: 53.84 (+0.73)

Stocks Surge At Starting Bell; Mylan, Expedia, GoPro Rocket
at Investor's Business Daily - Fri Oct 31, 9:36AM CDT
Stocks sprinted out of the starting gate Friday, with economic news, quarterly reports and international markets all adding lift. The Nasdaq staked out an early lead, up 1.2%, asMylan (MYL), Analog Devices (ADI) and Expedia (EXPE) all opened more...
AMBA: 49.03 (+1.89), GPRO: 75.37 (-3.69), EXPE: 86.11 (+1.00), ADI: 50.35 (+0.11), MYL: 53.84 (+0.73), MELI: 136.35 (+1.60)

Mylan (MYL) Highlighted As Momo Momentum Stock
at The Street - Fri Oct 31, 8:50AM CDT
Trade-Ideas LLC identified Mylan (MYL) as a momo momentum candidate
MYL: 53.84 (+0.73)

Mylan Beats, Raises Earnings Guidance; Abbott Deal on Track - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:00AM CDT
Mylan (MYL) reported third quarter 2014 earnings of $1.16 per share.
MNK: 93.09 (+2.03), ABT: 44.06 (+0.69), ACT: 245.71 (-0.20), MYL: 53.84 (+0.73)

Is Mylan's Lively Third Quarter the Start of Something Special?
Dan Carroll, The Motley Fool - Motley Fool - Thu Oct 30, 8:51PM CDT
The market has undergone a topsy-turvy second half of 2014; but for investors in leading generic drugmaker Mylan , the year's brought a bountiful harvest. Mylan's stock has rocketed up more than 20% year to date, with shares vaulting higher by more...
MYL: 53.84 (+0.73), TEVA: 58.11 (+0.41)

Mylan's (MYL) CEO Heather Bresch on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 8:30PM CDT

MYL: 53.84 (+0.73)

MYLAN
at Investor's Business Daily - Thu Oct 30, 6:13PM CDT
MYLAN (MYL), a drugmaker, said Q3 EPS rose 41.5% to $1.16, topping views by 2 cents, and sales grew 17.9% to $2.08 bil, beating forecasts for $2.06 bil. Shares rose 1.2% to 53.
MYL: 53.84 (+0.73)

Pfizer's Trumenba Gains Accelerated Approval in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:04PM CDT
Pfizer Inc.'s (PFE) Trumenba received accelerated FDA approval for prevention of invasive disease caused by Neisseria meningitidis serogroup B in people aged 10 - 25 years.
MNK: 93.09 (+2.03), ACT: 245.71 (-0.20), PFE: 30.25 (+0.33), MYL: 53.84 (+0.73)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CGX Hits Big Stage with New Obstacle Racing Shoes

A Bold Step into Obstacle Racing Today, CGX is shaking things up in the world of obstacle racing. The Chinese footwear brand launched its CGX&OCR R1010 and R1020 shoes right at the UIPM 2026 Obstacle World Championships in Beijing. Talk about a grand entrance. Targeting high-stakes international competition, these shoes are set to redefine how athletes tackle those...

California's Insurance Shake-up: What It Means

There are plenty of rules in life that seem useless until suddenly they're not. California just passed a few fresh ones aiming to rein in the insurance sector. Zap your attention over to three new bills targeting fair insurance payouts and boosting coverage availability. It's a gust of wind in a typically frustrating insurance landscape, especially for the folks who've...

HashKey and ONERWAY Pave New Routes for Digital Payments

New World of On-Chain Payments The landscape of on-chain payments is shifting like sands in a desert storm, but this time HashKey's Settlement Protocol (HSP) ties up with ONERWAY, giving a new direction. These players are looking to redefine how merchants transact with digital currency, tying up loose ends with fiat systems. Strategic Partnership: What’s At Stake? When...

Vanda Pharmaceuticals Steps Into September Investor Talks

Vanda Pharmaceuticals Heads Into Key Investor Spotlights In the relentless quest for market edge, Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is setting the stage for what could be some telling moments in September 2026. Investors with a keen interest in the pharmaceutical realm should seat themselves upfront as Vanda takes the floor in a series of pivotal conferences. Each...

Travel Smart: Support Wildlife, Avoid Exploitation

Rethink Wildlife Tourism for Ethical Travel You ever stopped to think about what those so-called wildlife attractions are really selling? It’s a feel-good illusion wrapped up in exploitation. Travelers often see animals as part of the backdrop of their holiday stories, but the reality is far from picturesque. Behind the photo ops, there's typically a grim story of...

TPx Pivots Post-Bankruptcy, Rebuilding for New Growth

TPx Rebounds with Stronger Foundation Folks, TPx just got itself a fresh pair of legs to stand on. Emerging from the labyrinth of Chapter 11 bankruptcy, TPx has managed to shave off a cumbersome load of debt and cement a pathway to long-term success. A court nod from the U.S. Bankruptcy Court for the Southern District of Texas confirmed their reorganization plan. It's a...

Scienjoy's Strategic Stake in Education: Bold Move?

Testing the Waters with Education Stake Talk about mixing oil and water. Scienjoy Holding Corporation, those tech-savvy folks from China's live streaming circles, have set their sights on education with a hefty 29.9% stake in Leader Education Limited. For HK$102.69 million, that’s about US$13.1 million, they’re jumping into an industry with a different flavor....

Scientel Solutions Connects North Central Athletes on Road

Boosting Connectivity for Student-Athletes Here's a nugget that slips under the radar unless you're looking with both eyes open: Scientel Solutions, from Aurora, Illinois, is shaking up the connectivity game for North Central College's athletic department. These folks have realized something many don't quite grasp—keeping student-athletes connected is no luxury; it's...

Decaf Coffee Market Grows to $5.2B by 2031 Amidst Tech Advances

The java crowd is waking up to a new trend that's more than just a flash in the mug. We're looking at a market shift where the decaffeinated coffee scene is steaming ahead, geared up for a whopping $5.2 billion valuation by 2031, growing at a tidy 7% CAGR. Yeah, you read that right. So, what's brewing that's making this market percolate? Riding the Wave of...

L.L.Bean Teams with Drake and Ann Michael Maye

The New Faces of L.L.Bean's Tradition Ah, here we go again with L.L.Bean, spicing things up with a bit of southern flair. This time they've reeled in the Mayes—Drake, that hotshot quarterback from the Patriots, and his better half, Ann Michael. A surprise duo, sure, but that's the kind of refresh the century-old brand could use. They’re all about making New England...